Comparison and Validation of Long-Term Bleeding Events for Academic Bleeding Risk (ARC-HBR) Criteria and Contemporary Risk Scores for Percutaneous Coronary Intervention With a Second-Generation Drug Eluting Stent

Koya Okabe(Kurashiki Central Hospital), Kazushige Kadota(Kurashiki Central Hospital), Masanobu Ohya(Kurashiki Central Hospital), Kohei Osakada(Kurashiki Central Hospital), Akihiro Ikuta(Kurashiki Central Hospital), Yasushi Fuku(Kurashiki Central Hospital), Yuki Shima(Kurashiki Central Hospital), Katsuya Miura(Kurashiki Central Hospital), Hiroyuki Tanaka(Kurashiki Central Hospital), Shunsuke Kubo(Kurashiki Central Hospital), Kotaro Takahashi(Kurashiki Central Hospital), Takeshi Tada(Kurashiki Central Hospital), Yuya Taguchi(Kurashiki Central Hospital)
Circulation Journal
April 8, 2022
10.1253/circj.cj-21-0901
Cited by 12

Related Papers

Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
|JAMA|2019|848
Antiplatelet Therapy and Stent Thrombosis After Sirolimus-Eluting Stent Implantation
|Circulation|2009|358
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
|JAMA Cardiology|2022|313
Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent
|Journal of the American College of Cardiology|2013|204
Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO‐Kyoto Thrombotic and Bleeding Risk Scores
|Journal of the American Heart Association|2018|198